

Department of Legislative Services
Maryland General Assembly
2022 Session

FISCAL AND POLICY NOTE
First Reader

House Bill 755 (Delegate Krebs, *et al.*)
Health and Government Operations

Pharmacy Benefits Managers - Prohibited Actions

This bill prohibits a pharmacy benefits manager (PBM) from (1) engaging in “spread pricing”; (2) denying a pharmacy the right to participate in a policy or contract with the PBM if the pharmacy or pharmacist meets specified terms and conditions; (3) taking more than 30 days to review an application to participate in a policy or contract with the PBM; or (4) setting different fees for a beneficiary’s copay based on whether a pharmacy or pharmacist is affiliated with an independent or chain pharmacy. These provisions apply to PBMs that contract with a Medicaid managed care organization (MCO) and PBMs that contract with carriers. The bill subjects all PBMs to specified provisions regarding information on and sales of prescription drugs and use of specific pharmacies and prohibits a PBM from requiring a beneficiary to use a mail order pharmacy. The bill also alters the definition of “purchaser” to include an insurer, a nonprofit health services plan, or a health maintenance organization (collectively known as carriers). **The bill takes effect January 1, 2023, and applies to all policies or contracts issued, delivered, or renewed in the State on or after that date.**

Fiscal Summary

State Effect: Minimal special fund revenue increase for the Maryland Insurance Administration (MIA) in FY 2023 from the \$125 rate and form filing fee; review of filings can be handled with existing budgeted resources. Likely no effect on Medicaid or the State Employee and Retiree Health and Welfare Benefits Program, as discussed below. Application of existing penalties is not anticipated to materially affect State finances.

Local Effect: Any impact on the cost of prescription drugs or PBM services for local governments under the bill is indeterminate. Revenues are not affected.

Small Business Effect: Meaningful.

Analysis

Bill Summary: “Spread pricing” means the model of prescription drug pricing in which a PBM charges a purchaser a contracted price for a prescription drug that differs from the amount the PBM directly or indirectly pays the pharmacist or pharmacy for the prescription drug dispensed by the pharmacist or pharmacy.

All PBMs are prohibited from requiring that a beneficiary use a specific pharmacy or entity to fill a prescription if the PBM (or a corporate affiliate of the PBM) has an ownership interest in the pharmacy or entity or vice versa, and from requiring that a beneficiary use a mail order pharmacy to fill a prescription.

Furthermore, all PBMs may not prohibit a pharmacy or pharmacist from (1) providing a beneficiary with information regarding the retail price for a prescription drug or the amount of the cost share for which the beneficiary is responsible for a prescription drug; (2) discussing with a beneficiary information regarding the retail price for a prescription drug or the amount of the cost share for which the beneficiary is responsible for a prescription drug; or (3) if a more affordable drug is available than one on the purchaser's formulary and the requirements for a therapeutic interchange are met, selling the more affordable alternative to the beneficiary.

Current Law: Title 15, Subtitle 16 of the Insurance Article governs PBMs. A PBM is a business that administers and manages prescription drug benefit plans. A PBM must register with MIA prior to providing pharmacy benefits management services.

“Purchaser” means a person that offers a plan or program in the State, including the State Employee and Retiree Health and Welfare Benefits Program, that (1) provides prescription drug coverage or benefits in the State and (2) enters into an agreement with a PBM for the provision of pharmacy benefits management services.

A PBM that provides pharmacy benefits management services on behalf of a carrier may not prohibit a pharmacy or pharmacist from (1) providing a beneficiary with information regarding or discussing with the beneficiary the retail price for a prescription drug or the amount of the cost share for which the beneficiary is responsible or (2) if a more affordable drug is available than one on the purchaser's formulary and the requirements for a therapeutic interchange are met, selling the more affordable alternative to the beneficiary.

With the exception of a specialty drug, *a PBM that provides pharmacy benefits management services on behalf of a carrier* may not require a beneficiary to use a specific pharmacy or entity to fill a prescription if the PBM (or a corporate affiliate) has an ownership interest in the pharmacy or entity or vice versa.

If the Insurance Commissioner determines a PBM has violated any provision of Title 15, Subtitle 16 of the Insurance Article or a related regulation, the Commissioner may issue an order that requires the PBM to (1) cease and desist; (2) take specific affirmative action to correct the violation; (3) make restitution of money, property, or other assets; or (4) pay a fine. In addition to any other enforcement action taken, the Commissioner may impose a civil penalty of up to \$10,000 for each violation.

State Expenditures: According to the federal Centers for Medicare and Medicaid Services, spread pricing occurs when health plans contract with PBMs to manage their prescription drug benefits and PBMs keep a portion of the amount paid to them instead of passing the full payments on to pharmacies. Thus, there is a “spread” between the amount that the health plan pays the PBM and the amount the PBM reimburses the pharmacy. If spread pricing is not appropriately monitored and accounted for, a PBM can profit from charging health plans an excess amount.

MDH advises that all nine MCOs utilize PBMs for their respective pharmacy reimbursement programs. PBMs assist with the negotiations of rebates and costs, perform certain financial and clinical services, and monitor drug utilization. Use of PBMs may result in cost savings and added efficiencies. Spread pricing is prohibited in MCO contracts. Under Maryland regulations, any option for accessing pharmacy services by mail order may be implemented only at the request of an MCO enrollee, except for specialty drugs. However, if an MCO enrollee requests to use a retail pharmacy for specialty drugs, the MCO may not limit the enrollee to the use of a mail order pharmacy. Thus, expenditures for Medicaid MCOs are likely not impacted under the bill.

The Department of Budget and Management advises that the PBM contract for the State Employee and Retiree Health and Welfare Benefits Program’s prescription drug program does not include spread pricing, nor does it mandate use of mail order for prescription drugs. Only specialty drugs may be available via mail order from a specialty pharmacy. Thus, expenditures for the program are likely not impacted under the bill.

Small Business Effect: Small business pharmacies benefit from the prohibition on spread pricing, which likely results in higher reimbursement, as well as from the ability to participate in a policy or contract with a PBM if they meet specified terms and conditions.

Additional Comments: MDH advises that requiring PBMs to engage with any pharmacy that meets the terms of the PBM’s policy or contract has the potential to significantly impact the PBM’s ability to negotiate with drug manufacturers, which could result in reduced savings. Furthermore, to the extent PBMs cannot meet the 30-day deadline for reviewing new applications from pharmacies and pharmacists, any additional administrative costs are likely passed on in the form of higher costs to MCOs, the State Employee and Retiree Health and Welfare Benefits Program, and carriers.

Additional Information

Prior Introductions: None.

Designated Cross File: SB 689 (Senator Ready) - Finance.

Information Source(s): Department of Budget and Management; Maryland Department of Health; Maryland Insurance Administration; Department of Legislative Services

Fiscal Note History: First Reader - March 9, 2022
fnu2/ljm

Analysis by: Jennifer B. Chasse

Direct Inquiries to:
(410) 946-5510
(301) 970-5510